Market Research Logo

Asthma and Chronic Obstructive Pulmonary Disease: Asthma Ahead of COPD in Terms of Innovation with the Focus on Targeted Biologic Therapies for Severe Disease Phenotypes

Asthma and Chronic Obstructive Pulmonary Disease: Asthma Ahead of COPD in Terms of Innovation with the Focus on Targeted Biologic Therapies for Severe Disease Phenotypes

Summary

In terms of First-in-Class (FIC) product innovation, the Chronic Obstructive Pulmonary Disease (COPD) pipeline is lagging behind the asthma pipeline. Higher levels of First-in-Class (FIC) innovation in the asthma pipeline are focused on meeting the large unmet need for therapies which can treat severe asthma phenotypes.

Asthma and Chronic Obstructive Pulmonary Disease (COPD) are both highly prevalent, chronic, inflammatory diseases of the airways and lungs. The asthma market is highly saturated with relatively efficacious standard therapies and the Chronic Obstructive Pulmonary Disease (COPD)market is also highly saturated with therapies that help to prevent exacerbations of the disease. However, there is considerable unmet need for innovative new therapies for severe asthmatics who do not respond to the current standards of care, and treatments which can reverse the progression of Chronic Obstructive Pulmonary Disease (COPD).

First-in-Class (FIC) product development in Chronic Obstructive Pulmonary Disease (COPD) constitutes only a small fraction of the pipeline. Of the pipeline products which had a disclosed molecular target, only 31% are FIC products. In contrast, 41% of the asthma pipeline with a disclosed molecular target is a FIC product. Further to this, 66% of the First-in-Class (FIC) products in the Chronic Obstructive Pulmonary Disease (COPD) pipeline are found in the preclinical stage of development with no First-in-Class (FIC) products in Phase III development or later.

The industry average for First-in-Class (FIC) innovation within a disease area is approximately 40%, which means that not only is innovation in the Chronic Obstructive Pulmonary Disease (COPD) pipeline relatively low in comparison to the asthma pipeline, it is also much lower than the industry average. Combined with the lack of late-stage innovation, it is unlikely that any FIC products will be entering the Chronic Obstructive Pulmonary Disease (COPD) market in the near future.

There is a high unmet need for therapies that treat severe asthma and this is reflected in the asthma pipeline. Monoclonal antibodies (mAbs) are the second most common molecule type in the asthma pipeline, indicating high levels of interest in developing targeted biologic therapies for severe phenotypes of asthma. The asthma market is saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs) and inhaled corticosteroids (ICSs). Therefore, the development of targeted biologic therapies for severe phenotypes of asthma is one way that companies can penetrate the asthma market.

The most prevalent molecular target class in the asthma pipeline is cytokines/chemokines and their receptors, which account for 18% of the pipeline. This group itself is diverse, although interleukins (ILs) and IL receptors are by far the most numerous targets among the cytokines, with IL-33, IL-4, IL-5 and IL-17 being targeted most frequently. These ILs are heavily implicated in the inflammatory response, notably for their role in recruiting inflammatory cells such as eosinophils. The specificity of these therapies means they are highly effective in specific, more severe sub-types of asthma patients, such as those characterized by elevated levels of eosinophils.

The report Asthma and Chronic Obstructive Pulmonary Disease: Asthma Ahead of COPD in Terms of Innovation with the Focus on Targeted Biologic Therapies for Severe Disease Phenotypes, assesses First-in-Class (FIC) innovation across the asthma and Chronic Obstructive Pulmonary Disease (COPD) pipelines.

Scope

  • Both the asthma and COPD markets are highly saturated. Which drug classes are used to treat these disorders? How do the drug classes in the market compare with those in the pipelines?
  • There are 266 and 161 pipeline programs in active development for asthma and COPD, respectively. What proportion of these products are first-in-class? How does first-in-class innovation vary by indication, development stage and molecular target class?
  • Which molecular target classes are prominently represented in the first-in-class asthma and COPD pipelines? Which first-in-class targets have been identified as most promising for asthma and COPD, and is there any overlap?
  • Which companies are the key players within the asthma and COPD markets? Who has been involved in the most licensing and co-development deals for asthma and COPD products? Which first-in-class products have prior deal involvement?
Reasons to buy
  • Understand the current disease landscape with an overview of etiology, pathophysiology, disease classification and staging systems, epidemiology, and treatment options for both asthma and COPD.
  • Visualize the composition of the asthma and COPD markets in terms of dominant molecule types and molecular targets. This allows an understanding of any gaps in the current market.
  • Analyze and compare the asthma and COPD pipelines and stratify by stage of development, molecule type, and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products for each indication have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.
  • Recognize commercial opportunities by identifying first-in-class asthma and COPD pipeline products that have not yet been involved in licensing or co-development deals, and by analyzing company strategies in prior deals through case studies of key deals for asthma and COPD first-in-class products.


  • Asthma and COPD: Executive Summary
    • COPD Lagging Behind Asthma in Terms of Innovation
    • Innovation in Asthma Pipeline is Focused Towards Targeted Biologic Therapies for Severe Phenotypes of the Disease
    • FIC Innovation in COPD Pipeline is Concentrated at the Early Development Stages
  • Introduction
    • Catalyst
    • Related Reports
    • Upcoming Related Reports
  • Disease Overview
    • Etiology and Pathophysiology
      • Asthma
        • Table Risk Factors for Asthma
      • COPD
        • Table Risk Factors for COPD
    • Classification or Staging Systems
      • Asthma
        • Table Classification of Asthma by Severity
      • COPD
        • Table GOLD 2017 Assessment of Airflow Limitation in COPD
        • Table GOLD 2017 Assessment of Symptoms/Risk of Exacerbations in COPD
    • Sustained Innovation in Asthma and COPD
    • Epidemiology for Asthma and COPD
      • Table Asthma's Diagnosed Prevalent Cases (Millions), 2013–2023
      • Table COPD's Diagnosed Prevalent Cases (Millions), 2015–2025
    • Overview for Marketed Products
      • Table Figure 1: Global Asthma Market by Molecular Target and Molecule Type, 2019
      • Table Figure 2: Global COPD Market by Molecular Target and Molecule Type, 2019
  • Assessment of Pipeline Product Innovation
    • Overview
    • Pipeline by Stage of Development and Molecule Type
      • Asthma
        • Table Figure 3: Asthma, Global, Pipeline by Stage of Development and Molecule Type, 2019
      • COPD
        • Table Figure 4: COPD, Global, Pipeline by Stage of Development and Molecule Type, 2019
    • Pipeline by Molecular Target
      • Asthma
        • Table Figure 5: Asthma, Global, Pipeline by Molecular Target and Stage of Development, 2019
      • COPD
        • Table Figure 6: COPD, Global, Pipeline by Molecular Target and Stage of Development, 2019
    • Comparative Distribution of Programs Between the Market and Pipeline by Molecular Target Class
      • Asthma
        • Table Figure 7: Asthma, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2019
      • COPD
        • Table Figure 8: COPD, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2019
    • Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class
      • Asthma
        • Table Figure 9: Asthma, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2019
        • Table Figure 10: Asthma, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2019
      • COPD
        • Table Figure 11: COPD, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2019
        • Table Figure 12: COPD, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2019
    • Ratio of First-in-Class Programs to First-in-Class Molecular Target within the Pipeline
      • Asthma
        • Table Figure 13: Asthma, Global, Ratio of First-in-Class and Non-First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2019
      • COPD
        • Table Figure 14: COPD, Global, Ratio of First-in-Class and Non-First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2019
  • First-in-Class Molecular Target Evaluation
    • Overview
    • Asthma
      • Pipeline Programs Targeting Toll-Like Receptor 6
      • Pipeline Programs Targeting Signal Transducer and Activation of Transcription 6
      • Pipeline Programs Targeting Adhesion G Protein Coupled Receptor E1
      • Pipeline Programs Targeting Mucin 5AC and Mucin 5B
    • COPD
      • Pipeline Programs Targeting Macrophage Metalloelastase
      • Pipeline Programs Targeting Myristoylated Alanine Rich C Kinase Substrate
      • Pipeline Programs Targeting C-X-C Chemokine Receptors 1 and 2
    • Asthma and COPD
      • Pipeline Programs Targeting Anoctamin 1
      • Pipeline Programs Targeting Extracellular Calcium Sensing Receptor
  • Key Players and Deals
    • Overview
      • Regeneron and Sanofi Sign Co-Development Deal for Multiple Pipeline Assets
      • GlaxoSmithKline Enters Licensing Deal with Janssen to Expand Respiratory Offering
      • Amgen and AstraZeneca Co-development Deal for Several Monoclonal Antibodies
  • Appendix
    • Bibliography
    • Abbreviations
    • Methodology
      • Market Analysis
      • Overall Pipeline Analysis
      • First-in-Class Pipeline Analysis
      • First-in-Class Matrix Assessment
      • First-in-Class Molecular Target Evaluation
      • Key Players and Deals
    • About the Authors
      • Analyst
      • Therapy Area Director
      • Global Director of Therapy Analysis and Epidemiology
      • Global Head and EVP of Healthcare Operations and Strategy
    • About GlobalData
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report